Incyte, an American multinational pharmaceutical company, agreed to acquire Escient Pharmaceuticals, a clinical-stage drug discovery and development company, for $750m. “As a company dedicated to innovation and the discovery of transformative medicines, we are excited to add EP262 and EP547 to our portfolio. This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential. EP262 and EP547 are complementary additions to our portfolio, providing an opportunity to leverage our expertise, address the needs of patients with inflammatory diseases and additional potential launch opportunities starting in 2029,” Hervé Hoppenot, Incyte CEO.